View Post

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

In Clinical Trials by Barbara Jacoby

Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (NASDAQ: MBRX), recently recruited 3 patients in 6 …